RET and neoplasm: In a phase III trial, tumour responses confirmed that Cabozantinib is clinically active in all MTC subgroups, regardless of the genotype, with ORRs ranging from 34% (RET M918T positive subgroup) to 20% (RET M918T negative subgroup), while no objective responses were noticed in patients who received the placebo [172,173].